AN OPEN-LABEL, TOLERABILITY AND EFFICACY STUDY OF ZYN002 (CANNABIDIOL) Administered As A Transdermal Gel To Children And Adolescents With 22Q11.2 Deletion Syndrome (INSPIRE)

被引：0
|
作者：
Heussler, H. [1 ]
Cohen, J. [2 ]
Buchanan, C. [3 ]
O'Neill, C. [4 ]
Sebree, T. [4 ]
O'Quinn, S. [4 ]
机构：
[1] Childrens Hlth Queensland Hosp & Hlth Serv, Ctr Clin Trials Rare Neurodev Disorders, South Brisbane, Qld, Australia
[2] Genet Clin Australia, North Caulfield, Vic, Australia
[3] Greenwood Genet Ctr, Greenville, SC USA
[4] Zynerba Pharmaceut, Devon, PA USA
来源：
JOURNAL OF INTELLECTUAL DISABILITY RESEARCH | 2022年 / 66卷 / 8-9期
关键词：
22q.11.2; Anxiety; Cannabidiol; Deletion syndrome; Irritability;
D O I：
暂无
中图分类号：
G76 [特殊教育];
学科分类号：
040109 ;
摘要：
引用
收藏
页码：672 / 672
页数：1
相关论文
共 14 条
  • [1] An Open-Label, Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
    Heusslar, Helen
    Cohen, Jonathan
    Buchanan, Caroline
    O'Neill, Carol
    O'Quinn, Stephen
    Sebree, Terri
    Siegel, Steven
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 129 - 129
  • [2] An Open-Label, Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
    Heusslar, Helen
    Cohen, Jonathan
    Buchanan, Caroline
    O'Neill, Carol
    O'Quinn, Stephen
    Sebree, Terri
    Siegel, Steven
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 129 - 129
  • [3] AN OPEN-LABEL TRIAL ASSESSING SHORT- AND LONG-TERM TOLERABILITY AND EFFICACY OF ZYN002 (CANNABIDIOL) ADMINISTERED AS A TRANSDERMAL GEL TO CHILDREN AND ADOLESCENTS WITH 22Q11.2 DELETION SYNDROME (INSPIRE)
    Heussler, H.
    Duhig, M.
    Cohen, J.
    Buchanan, C.
    O'Neill, C.
    O'Quinn, S.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2023, 67 (09) : 808 - 809
  • [4] LONGER TERM TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY (BRIGHT [ZYN2-CL-030])
    Heussler, H.
    Duhig, M.
    Hurst, T.
    O'Neill, C.
    Gutterman, D.
    Palumbo, J. M.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2021, 65 (09) : 805 - 806
  • [5] A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
    Heussler, Helen
    Cohen, Jonathan
    Silove, Natalie
    Tich, Nancy
    Bonn-Miller, Marcel O.
    Du, Wei
    O'Neill, Carol
    Sebree, Terri
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2019, 11 (1)
  • [6] A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
    Helen Heussler
    Jonathan Cohen
    Natalie Silove
    Nancy Tich
    Marcel O. Bonn-Miller
    Wei Du
    Carol O’Neill
    Terri Sebree
    Journal of Neurodevelopmental Disorders, 2019, 11
  • [7] A PIVOTAL STUDY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME [CONNECT-FX (ZYN2-CL-016)]
    Hagerman, R.
    Berry-Kravis, E.
    Budimirovic, D.
    Erickson, C.
    Heussler, H.
    Tartaglia, N.
    Cohen, J.
    Sebree, T.
    Tich, N.
    Palumbo, J.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2021, 65 (09) : 805 - 805
  • [8] A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    Budimirovic, Dejan
    Erickson, Craig
    Heussler, Helen
    Tartaglia, Nicole
    Cohen, Jonathan
    Dobbins, Thomas
    Merikle, Elizabeth
    Sebree, Terri
    Tich, Nancy
    Palumbo, Joseph
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S226 - S227
  • [9] A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
    Elizabeth Berry-Kravis
    Randi Hagerman
    Dejan Budimirovic
    Craig Erickson
    Helen Heussler
    Nicole Tartaglia
    Jonathan Cohen
    Flora Tassone
    Thomas Dobbins
    Elizabeth Merikle
    Terri Sebree
    Nancy Tich
    Joseph M. Palumbo
    Stephen O’Quinn
    Journal of Neurodevelopmental Disorders, 2022, 14
  • [10] A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    Budimirovic, Dejan
    Erickson, Craig
    Heussler, Helen
    Tartaglia, Nicole
    Cohen, Jonathan
    Tassone, Flora
    Dobbins, Thomas
    Merikle, Elizabeth
    Sebree, Terri
    Tich, Nancy
    Palumbo, Joseph M.
    O'Quinn, Stephen
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2022, 14 (01)
12